Neuronetics, Inc. (STIM) Q4 2025 Earnings Call Transcript

Neuronetics hosted its Q4 2025 earnings call on March 17, 2026 and filed its annual report on Form 10‑K premarket today. Management (CEO Keith Sullivan, CFO Steve Pfanstiel) emphasized forward-looking statement disclaimers and discussed business topics including the Greenbrook integration and guidance-related issues, but provided no new financial metrics in the excerpt. Analysts from Westwicke, Canaccord, Piper Sandler and JMP participated in the call.

Analysis

Device makers that can capture both hardware sales and downstream treatment revenue stand to convert lumpy capital sales into recurring cash — a 10–20% uplift in clinic utilization typically moves gross-margin mix meaningfully because fixed-install amortization is already sunk. Owning or closely partnering with treatment sites also creates a second-order data advantage: faster real‑world outcomes shorten sales cycles with large payers and can compress commercial cycle time from years to quarters if used to win coverage decisions.

Primary near-term catalysts are utilization and payer wins, which are binary and operate on different cadences: utilization improvements show up within 3–9 months after clinic integration, while major payer coverage shifts take 6–24 months and are the bigger earnings multipliers. The largest tail risk is reimbursement/regulatory reversal — a payer pullback or an adverse safety signal would knock 30–50% off consensus IRR on installed base economics within a single quarter.

Consensus tends to treat device revenue and clinic economics as additive rather than multiplicative; that understates upside where modest utilization gains (10–15%) convert low-margin procedures into high-margin recurring programs. Conversely, the market is rightly skittish about execution-intensive roll-ups; timing and capex needs create 6–18 month execution windows where downside is concentrated even if the long-term thesis remains intact.

Key Decisions for Investors

• Long STIM (5% position): buy shares on underperformance into any 10–15% pullback; target +50% in 12 months if utilization improves 10–15% and payer wins begin, stop-loss at -30% to protect against reimbursement/regulatory shocks.
• Options play (asymmetric upside): buy 12–18 month STIM LEAP calls (limit size to 1–2% notional of portfolio) to capture optionality from payer decisions and integration milestones; pair with selling 3–6 month calls to finance if IV is elevated — expect >3:1 upside/downside if a clear payer win occurs within 12 months.
• Hedge pair (6–12 months): long STIM / short XBI equal notional to isolate device/clinic execution from broad biotech/regulatory volatility. This reduces sector beta and leaves idiosyncratic upside from utilization or coverage as the primary driver.